In less than two weeks, the country came together and collected over KGS 510 million (USD 5.9 million), displaying unprecedented unity and generosity.
No local clinical trial waiver despite change in rules, drugmakers knock on health ministry’s door
Drug regulator through executive order issued last August paved way for direct launch of certain categories of drugs approved ...
While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...
Over 95% of babies now diagnosed with SMA are treated with Zolgensma gene therapy, per Daniel Grant, vice president for ...
Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback